Financing translation: Analysis of the NCATS rare-diseases portfolio.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Abstract:
      The article offers information on the evaluation of potential risks and rewards of investing in a portfolio of the National Center for Advancing Translational Sciences (NCATS) rare diseases therapeutic development program. Topics discussed include lower costs and higher success rates but longer preclinical timelines for the NCATS projects; early-stage translational medical research and development; and expected return to equity and funding by patient advocacy groups and government agencies.